1
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                ---------------

                                    FORM 8-K
                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 30, 1997

                            PATHOGENESIS CORPORATION
             (Exact name of registrant as specified in its charter)


    Delaware                    0-27150                          91-1542150
(State or other               (Commission                     (IRS Employer
jurisdiction of               File Number)                   Identification No.)
incorporation)

               201 Elliott Avenue West, Seattle, Washington 98119
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (206) 467-8100

                                 Not Applicable
          (Former name or former address, if changed since last report)
   2
Item 5.  Other Events.

         Annexed hereto as Exhibit 1 is a copy of a press release issued by
PathoGenesis Corporation (the "Company") on January 30, 1997 announcing the
results of its Phase III clinical trials for TOBI(TM) for treatment of chronic
Pseudomonas aeruginosa lung infections in people with cystic fibrosis.

         In connection with the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, the Company is hereby filing as
Exhibit 2 cautionary statements identifying important factors that could cause
the Company's actual results to differ materially from those projected in
forward looking statements of the Company made by or on behalf of the Company in
the press release annexed hereto as Exhibit 1.

                                      - 2 -
   3
Item 7.  Exhibits

         1.       Press Release dated January 30, 1997.

         2.       Cautionary Statements for Purposes of the "Safe Harbor"
                  Provisions of the Private Securities Litigation Reform Act of
                  1995.


                                      - 3 -
   4
                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed by the undersigned
hereunto duly authorized.



                                            PATHOGENESIS CORPORATION
                                            (Registrant)



                                          By: /s/ Alan R. Meyer
                                             -------------------------------
                                               Alan R. Meyer
                                                  Senior Vice President and
                                                  Chief Financial Officer


Date: January 31, 1997


                                      - 4 -
   5
                                  EXHIBIT INDEX


                 Exhibit                                     Page Number

1.       Press Release dated January 30,
         1997.

2.       Cautionary Statements for Purposes
         of the "Safe Harbor" Provisions of
         the Private Securities Litigation
         Reform Act of 1995.